Tackling cancer
At Johnson & Johnson, we are driven by our bold vision to eliminate cancer. Together, we work diligently to get in front of cancer and will never settle until the disease is behind everyone.
From discovery to development to delivery of transformational therapies and technological solutions, we are collaborating with the brightest minds to advance the next wave of treatments—and potential cures.
Our transformative portfolio is setting new standards of care for some of the most difficult to treat cancers, including multiple myeloma, B-cell malignancies, bladder cancer, prostate cancer, and lung cancer. Through the convergence of our innovative medicine and medical device expertise and technology, we are striving to change the future of cancer.
From discovery to development to delivery of transformational therapies and technological solutions, we are collaborating with the brightest minds to advance the next wave of treatments—and potential cures.
Our transformative portfolio is setting new standards of care for some of the most difficult to treat cancers, including multiple myeloma, B-cell malignancies, bladder cancer, prostate cancer, and lung cancer. Through the convergence of our innovative medicine and medical device expertise and technology, we are striving to change the future of cancer.
Innovating in Health&Care
-
5 ways Johnson & Johnson is innovating in medicines and therapies
From rare diseases to all-too-common cancers, Johnson & Johnson is on a mission to improve treatment options for people around the globe. Learn more about how the company is working to create new therapies for IBD, lung cancer, major depressive disorder, bladder cancer, myasthenia gravis and more. -
Understanding head and neck cancer
This complex type of cancer can cause malignancies of the mouth, throat, larynx and nasal cavity. Find out how Johnson & Johnson is innovating to change the current treatment paradigm.
-
Striving for a cure for multiple myeloma: What HCPs need to know
Jordan Schecter, M.D., leader of Johnson & Johnson’s end-to-end development strategy for multiple myeloma, shares insight on the evolving treatment landscape of this rare blood cancer. -
“Our goal is a solution for every bladder cancer patient”
Meet Christopher Cutie, M.D., the Johnson & Johnson scientist who’s helping change the treatment landscape for people with bladder cancer, the tenth most common cancer in the world. -
Using your own cells to fight cancer
Cell therapy is bringing the world one step closer to eliminating cancer. Here’s how Johnson & Johnson has treated more than 10,000 patients and counting with this cutting-edge therapy.
Our oncology disease areas
-
Find information about clinical trials
Read moreYou are now leaving jnj.com.
This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use. Click continue to proceed.
You are now leaving jnj.com.
This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use. Click continue to proceed.
-
Learn about our development pipeline
Read moreYou are now leaving jnj.com.
This link will take you to a different Johnson & Johnson website, where different laws and regulations may apply.
You are now leaving jnj.com.
This link will take you to a different Johnson & Johnson website, where different laws and regulations may apply.
The race to detect, diagnose and treat lung cancer
Lung cancer incidence and mortality rates show no sign of slowing. But through innovation in robotics, biosurgery, energy delivery and more, the fight for earlier diagnosis and better treatment options is gaining traction.
Getting in front of cancer
Every year, roughly 2 million people in the U.S. are newly diagnosed with cancer. But new scientific breakthroughs—including ones made at Johnson & Johnson—have dramatically changed the prognosis of many of these patients.
Meet two brothers who are revolutionizing the way scientists develop treatments for cancer
Justin and Colin Farlow share how their next-generation cell and gene therapies are helping Johnson & Johnson in its quest to get in front of cancer.
Five lives, five journeys: Living in front of cancer
Perspectives from survivors, caregivers and advocates on what it means to live, hope and move forward with cancer.
“Lung cancer wasn’t even on my radar. Then I was diagnosed.”
The disease is often detected late—which can have fatal consequences. But thanks to innovations in diagnostic tools, there’s a way to catch lung cancer earlier. Here’s how early detection saved one woman’s life.
Learn about two Johnson & Johnson nurse educators who are dedicated to teaching cancer care providers
Jennifer Huff and Jacqui Mellott are two of Johnson & Johnson’s oncology clinical educators—a team of 56 nurses who visit hospitals and infusion centers to help providers understand and stay up to date with treatments.
Johnson & Johnson’s Oncology Care Index uncovers barriers and opportunities to improve cancer care in the U.S.
Learn what 500 oncology professionals say about the current state of cancer care
5 things we now know about bladder cancer
Paradigm-shifting new therapies are helping people with the disease lead longer, more comfortable lives. Learn how Johnson & Johnson is helping to change the treatment landscape.
Our work in Interventional Oncology
This Johnson & Johnson Research & Development enterprise group integrates the expertise of both Johnson & Johnson Innovative Medicine and Medtech, aiming to develop intratumoral treatments.